CORRECTION: Caribou Biosciences Q2 Adj. EPS $(0.35) Beats $(0.39) Estimate, Sales $2.667M Beat $2.465M Estimate

Caribou Biosciences (NASDAQ: CRBU) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.39) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.667 million which beat the analyst consensus estimate of $2.465 million by 8.19 percent. This is a 23.01 percent decrease over sales of $3.464 million the same period last year.